SecBot SecBot
PRESS-RELEASE ·Filed Nov 9, 2026

AEON

AEON Biopharma Inc
NEUTRAL
Impact 4/10
Horizonmonths Processed7d 15h ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

Monitor for FDA feedback on the IND and any updates on the CMAP study initiation timeline. The company's ability to secure additional capital to fund development is a key risk given the $11M market cap and no revenue.

DirectionNeutral
Confidencehigh
Horizonmonths

ABP-450

▼ Bearish Named in this press release
Impact
Phase
Pre-approval biosimilar (351(k)) development — analytical comparability stage; no active Phase 2/3 trial in local data a
Time to market
Unknown — several years at best. The program is still in FDA pathway-alignment (Type 2a meeting held Jan 2026; Type 2b planned 2H26); a BLA has not been filed and five-year milestone warrants are tied to Phase 3 trial initiation, so US approval is likely late-2020s or later if the biosimilar path succeeds.
Next catalyst
None dated

What to watchTreat the ~$6.70 two-analyst price target as a stale artifact set before the July 2026 re-IPO dilution (stock trades ~$0.26, near its 52-week low of $0.222). Watch the FDA Type 2b meeting in 2H26, its minutes trigger expiry of the two-year milestone warrants and could unlock up to $34M in additional gross proceeds, a potential double-edged catalyst: capital in, but at heavy dilution. Also monitor NYSE American compliance status after the August 3, 2026 deadline to regain listing standards.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$0.1818
T+0 close · Nov 9, 2026 · via day close
Latest settled
−22.61%
T+5 · $0.1407
Vs SPY
−20.91%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $0.1818entry
  2. T+1 · 7d ago −1.38%α −1.01% · $0.1793
  3. T+5 · 17h ago −22.61%α −20.91% · $0.1407
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AEON Biopharma submitted an IND to the FDA for a CMAP pharmacodynamic study of its ABP-450 biosimilar to BOTOX, following a recent Type 2b meeting. The study is designed to generate comparative evidence of neuromuscular activity, with initiation expected in Q1 2027. The filing is a procedural milestone in the biosimilar development pathway, with no financial data or regulatory decision announced.

Key Facts

  • AEON submitted an IND for a CMAP pharmacodynamic study comparing ABP-450 to BOTOX.
  • The submission follows a Biosimilar Biological Product Development Type 2b meeting with the FDA.
  • Study initiation expected in Q1 2027.
  • AEON is pursuing a 351(k) biosimilar pathway with a totality-of-evidence strategy that may avoid a standalone comparative efficacy study.
  • The U.S. therapeutic neurotoxin market exceeds $3.5 billion annually.
  • AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the U.S., Canada, EU, UK, and other territories.

Financial Impact

No financial figures disclosed; market opportunity cited as >$3.5B annually for U.S. therapeutic neurotoxin market.

Risk Factors

  • FDA may require additional studies beyond the planned CMAP study.
  • Company needs sufficient capital to fund development; $11M market cap suggests limited financial runway.
  • Biosimilar approval is uncertain and subject to regulatory requirements.
  • Document contains text addressed to automated readers (forward-looking statements boilerplate).

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3398338

Track record

22 reports on AEON

Performance horizon

8 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +44.50% at T+60 after the Jul 9, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry price pending
  2. Nov 16, 2026today Press Release Neutral 5/10 Entry $0.1410 Now $0.1410 +0.00% settles Nov 24
  3. Nov 13, 20263d ago SC 13G Neutral 4/10 Entry $0.1610 Now $0.1410 −12.42% settles Nov 23
  4. Nov 10, 20266d ago SC 13D/A Neutral 3/10 Entry $0.1793 Now $0.1410 −21.36% settles Nov 17
  5. Nov 9, 20267d ago Press Release Neutral 4/10 Viewing Entry $0.1818 to $0.1407 Now $0.1410 −22.44% ▼ −22.61% −20.91% vs SPY
  6. Nov 3, 202613d ago 8-K Neutral 4/10 Entry $0.2122 to $0.1793 Now $0.1410 −33.55% ▼ −15.50% −14.92% vs SPY
  7. Oct 26, 202621d ago DEF 14A Neutral 3/10 Entry $0.2483 to $0.2122 Now $0.1410 −43.21% ▼ −14.54% −12.55% vs SPY
  8. Oct 23, 202624d ago 8-K Neutral 4/10 Entry $0.2400 to $0.2740 Now $0.1410 −41.25% ▲ +14.17% +15.43% vs SPY
  9. Sep 30, 20266w ago 8-K Bullish 7/10 Entry $0.3000 to $0.3110 Now $0.1410 −53.00% ▲ +3.67% +1.75% vs SPY
  10. Aug 21, 202612w ago 3 Neutral Not scored Entry $0.1974 to $0.2959 Now $0.1410 −28.57% ▲ +49.90% +49.43% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens Wed (9h 46m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026